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Abstract A sensitive, simple and selective spectrofluori-
metric method was developed for the determination of
oxamniquine (OXM) in pharmaceutical formulations and
biological fluids. The method is based on the reaction
between the drug and 1-dimethylaminonaphthalene-5-
sulphonyl chloride (dansyl chloride) in presence of
0.5 M sodium carbonate (pH 10) to yield a highly
fluorescent derivative that is measured at 445 nm after
excitation at 335 nm. The different experimental param-
eters affecting the development and stability of the
reaction product were carefully studied and optimized.
The fluorescence concentration plot was rectilinear over
the range of 0.02–0.2 μgm l
−1 with a lower detection
limit (LOD) of 0.007 μgm l
−1 and limit of quantitation
( L O Q )o f0 . 0 2μgm l
−1. The proposed method was
successfully applied to the analysis of commercial capsules.
The results obtained were in good agreement with those
obtained using the official spectrophotometric method.
Furthermore, the method was applied for the determination
of oxamniquine in spiked human plasma, the mean %
recovery (n=4) is 97.77±1.19. A proposal of the reaction
pathway was presented.
Keywords Oxamniquine.1-dimethylaminonaphalene-
5-sulphonyl chloride.Dosageforms.Spikedhumanplasma
Introduction
Oxamniquine (OXM), 1,2,3,4-tetrahydro-2[(isopro-
pylamino methyl]-7-nitro-6-quyinoline methanol is an anti-
schistosomal agent that is indicated for the treatment of
schistosoma mansoni (intestinal schistosomiasis) infection
(Fig. 1). It has been shown to inhibit DNA, RNA and
protein synthesis in schistosomes. The oral bioavailability
of oxamniquine is good and effective plasma levels are
achieved in 1–1.5 h [1].
Oxamniquine is the subject of a monograph in the USP
(XXIII) [2] whereby a spectrophotometric method is recom-
mended for its determination, whether in its pure form or in
capsules. Several methods have been published for the
determination of OXM, either per se or in pharmaceutical
preparations and biological fluids. These methods include:
spectrophotometry [3–5], non-aqueous titration [6], gas
chromatography [7], HPLC [8–13], capillary electrophoresis
[11], polarography [14], flow injection analysis [15], cyclic
voltammetry [16] and fluorimetry [17].
All these methods are either insufficiently sensitive or
tedious and require highly sophisticated and dedicated
instrumentation [8–13]. This led us to study the reaction
of oxamniquine with dansyl chloride to develop simple and
sensitive spectrofluorimetric method for its determination in
pharmaceutical preparations and biological fluids. Dansyl
chloride is a useful derivatizing agent for primary amines,
secondary amines, imidazoles and phenols, etc.. Several
pharmaceutical compounds have been determined through
this approach [18–24].
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Experimental
Apparatus
The spectrofluorimetric measurements were recorded using
ARF-1501 Shimadzu Spectrofluorometer, equipped with
Xenon arc lamp.
Materials and reagents
All reagents and solvents were of analytical reagent grade
– Oxamniquine pure sample was kindly provided by
Pfizer (Sandwich, UK).
– Capsules containing 250 mg of Oxamniquine each
(Vansil capsules) were obtained from commercial
sources in the local market.
– 1-Dimethyl aminonaphthalene-5-sulphonyl chloride
(dansyl chloride), purchased from Sigma (St. Louis,
USA). A stock solution containing 0.1% of dansyl
chloride was freshly prepared in acetone and was
further diluted with the same solvent to obtain 0.001%
solution.
– Sodium carbonate (BDH, UK) 0.5 M aqueous solution
(pH 10).
– Sodium hydroxide (BDH, UK) 1 M aqueous solution.
– Isobutylmethyl ketone (IBMK) (Merck, Darmstadt,
Germany).
– Plasma was kindly provided by Mansoura University
Hospital, and kept frozen until assay after gentle
thawing.
– Methanol and diethyl ether (Merck, Darmstadt,
Germany).
Standard solutions
A stock solution was prepared by dissolving 20.0 mg of
OXM in 20 ml of acetone and 80 ml of 0.5 M sodium
carbonate solution. This solution was further diluted with
the same solvent mixture as appropriate. The standard
solutions were stable for seven days when kept in the
refrigerator.
General procedure
Aliquots of OXM standard solution were transferred into a
series of 10 ml volumetric flasks. 0.7±0.1 ml of 0.001%
of dansyl chloride reagent was added, followed by 0.4 ml
of acetone and mixed well. The reaction mixture was left
for 30 min, and then completed to the mark with IBMK.
the reaction mixture was allowed to stand for 10 min. The
fluorescence intensity of the reaction product was mea-
sured at 445 nm after excitation at 335 nm. Blank
experiment was carried out simultaneously. The corrected
fluorescence intensity was plotted vs the final drug
concentration (μgm l
−1) to get the calibration graph.
Alternatively, the corresponding regression equation was
derived.
Applications
Procedure for commercial capsules
The content of ten capsules were emptied, and mixed well.
A weighed quantity of the powder equivalent to 5.0 mg
OXM was transferred into a small conical flask, and
extracted with 2×10 ml of methanol. The extract was
filtered into 25 ml volumetric flask. The conical flask was
washed with several milliliters of methanol. The washing
was passed into the same volumetric flask, and the
combined extract was evaporated to dryness on a boiling
water bath. The residue was dissolved and diluted to
volume with a mixture of 5 ml of acetone and 20 ml of
0.5 M of sodium carbonate solution. Aliquots covering the
working concentration range (cited in Table 1)w a s
Table 1 Performance data of the proposed method
Parameter Proposed method
Concentration range (μgm l
−1) 0.02–0.2
Minimum detection limit, LOD (μgm l
−1) 0.007
Limit of Quantification, LOQ(μgm l
−1) 0.02
Correlation coefficient (r) 0.9999
Slope 3,473.114
Intercept 0.574
Sy/x 1.273
Sa 7.733
Sb 8.965
% Error 0.28
Sy/x = standard deviation of the residuals
Sa = standard deviation of the intercept of regression line
Sb = standard deviation of the slope of regression line
% Error = RSD%/√ n
N
H
CH2 NH
H
C (CH3)2
O2N
HOH2C
Fig. 1 Structural formula of oxamniquine
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procedure” was then applied. The nominal content of the
capsules was determined either from the calibration curve
or using the corresponding regression equation.
Procedure for spiked human plasma
A stock solution containing 20 μgm l
−1 of OXM was
prepared. Control samples of plasma was spiked with
different quantities of OXM to give a final drug concentra-
tion cited in Table 5. One molar NaOH (0.8 ml) was added
to 1.0 ml of the spiked plasma and shaken genteelly. The
solution was vortexed with 3×5 ml of diethylether for
2 min, then centrifuged at 2,500 rpm for 5 min. The
resulting supernatant was evaporated to dryness under
nitrogen at ambient temperature. The residue was dissolved
and diluted to volume with a mixture of 5 ml of acetone and
20 ml of 0.5 M of sodium carbonate solution. Aliquots
covering the working concentration range was transferred
into 10 ml volumetric flasks. The recommended procedures
were then applied. The nominal content of the drug was
determined using the corresponding regression equation.
Results and discussion
Dansyl chloride was first introduced for the determination
of some primary, secondary amines, imidazoles and
phenols [18–20].
In recent reports. DNS was further used as a fluorogenic
reagent for the determination of some pharmaceutical
compounds [21–24].
In the present study, OXM was found to react with
Dansyl chloride at pH 10.0 forming a highly yellow
fluorescent derivative with l maximum emission at
445 nm after excitation at 335 nm (Fig. 2).
Optimization of experimental parameters
The spectrofluorimetric properties of the colored product as
well as the different experimental parameters affecting the
development of the reaction product and its stability were
carefully studied and optimized. Such factors were changed
individually while the others were kept constant. The
factors include pH, concentration of the reagent, type of
buffer, temperature, reaction time and dilution time.
Effect of pH
The influence of pH on the fluorescence intensity of the
reaction product was studied. Maximum fluorescence inten-
sity was obtained upon using mixture of acetone and 0.5 M
sodium carbonate solution. The pH of the reaction mixture
wasfoundtobe10.0.pH10wasfoundtobetheoptimumpH
for dansylation because labeling of most amino acids,
amines, imidazoles and phenols has been found to be
optimal at pH 9.5–10.5 [25]. The rate of dansylation process
was found to increase with increasing the pH value this is
due to an increase in the rate of hydrolysis of dansyl
chloride into dansyl hydroxide [25]. The latter shows strong
fluorescence and hence interferes seriously in the determi-
nation. However, under the proposed chosen conditions and
wavelengths used, there was no interference arising from
any dansyl hydroxide formed, as indicated by the low
fluorescence intensity of the reagent.
Effect of concentration of dansyl chloride
The influence of the concentration of dansyl chloride was
studied using different volumes of 0.001% of the reagent
solution. It was found that, the reaction of dansyl chloride
with OXM started upon using 0.1 ml of the reagent in the
presence of sodium carbonate (pH 10.0). Increasing the
volume of the reagent, produces a proportional increase in
the fluorescence intensity of the reaction product up to
0.6 ml and remains constant up to 0.8 ml. Therefore, 0.7±
0.1 ml of 0.001% of dansyl chloride solution was chosen as
the optimal volume of the reagent (Fig. 3).
Effect of temperature
Increasing the reaction temperature higher than the room
temperature would result in a subsequent decrease in the
fluorescence intensity of the reaction product.
Effect of reaction time
Different time intervals were tested to ascertain the time
after which the solution attains its highest fluorescence
intensity. It was found that after 30 min, the reaction
Fig. 2 Fluorescence spectra of A and B excitation and emission
spectra of blank. Fluorescence spectra of A′ and B′ excitation and
emission spectra of oxamniquine (0.2 μgm l
−1) with dansyl chloride at
pH 10.0
J Fluoresc (2008) 18:349–355 351 351product reaches the highest fluorescence intensity (Fig. 4)
and remains stable at room temperature for 20 min.
Effect of diluting solvent
Different solvents were tried to dilute the reaction mixture
through out the study. It was observed that isobutyl methyl
ketone gave the highest fluorescence intensity. Dilution
with 0.5 M sodium carbonate solution, water, acetone–
water produced almost very week fluorescence and did not
reduce the blank fluorescence intensity. While upon using
isobutyl methyl ketone, the fluorescence intensity attained
its highest value, this was attributed to the low fluorescence
value of the reagent.
Effect of dilution time
Dilution times were tested to ascertain the time after which
the solution attains its highest fluorescence. It was found
that dilution with IBMK after 10 min, the reaction product
reaches its highest fluorescence intensity (Fig. 5).
Analytical performance
Validation of the proposed methods The validity of the
method was tested regarding; linearity, specificity, accuracy,
repeatability and precision according to ICH Q2B recom-
mendations [26].
Linearity
By using the above procedure, linear regression equation was
obtained. The regression plots showed that there was a linear
dependence of the fluorescence intensity on the concentration
of the drug over the ranges cited in Table 1. Linear regression
analysis of the data gave the following equation:
F ¼ 0:574 þ 3;473:114Cr ¼ 0:9999 ðÞ
where F is the fluorescence intensity, C is the concentration
of the drug in μgm l
−1 and r is the correlation coefficient.
The limit of quantification (LOQ) was determined by
establishing the lowest concentration that can be measured
according to ICH Q2B [26]. The results are shown in
Table 1. The limits of detection (LOD) were determined by
establishing the minimum level at which the analyte can be
reliably detected, and the results are also abridged in Table 1.
LOQ and LOD were calculated according to the
following equation [26]:
LOQ ¼ 10σ=S
LOD ¼ 3:3σ=S
Where σ: is the standard deviation of the intercept of
regression line. S: is the slope of the calibration curve.
The proposed methods were evaluated for the accuracy
as percent relative error (% Er) and the precision as percent
relative standard deviation (% RSD) (Tables 1 and 2).
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Fig. 4 Effect of reaction time of on the fluorescence intensity of the
reaction product of oxamniquine (0.2 μgm l
−1) with dansyl chloride
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Fig. 5 Effect of dilution time on the fluorescence intensity of the
reaction product of oxamniquine (0.2 μgm l
−1) with dansyl chloride
volume of 0.001% dansyl chloride
(mL)
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Fig. 3 Effect of volume of dansyl chloride (0.001%) on the
fluorescence intensity of the reaction product of oxamniquine
(0.2 μgm
−1) at pH 10.0
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To test the validity of the proposed method it was applied to
the determination of authentic sample of OXM over the
working concentration range. The results obtained were in
good agreement with those obtained using official method.
Using Student’s t test and variance ratio F test, [27]
revealed no significant difference between the performance
of the two methods regarding the accuracy and precision,
respectively (Table 2).
The validity of the methods was proved by statistical
evaluation of the regression lines, using the standard
deviation of the residuals (Sy/x), the standard deviation of
the intercept (Sa) and standard deviation of the slope (Sb).
The results are abridged in Table 1. The small values of the
figures point out to the low scattering of the points around
the calibration line and high precision.
Precision
a. Repeatability
The repeatability was performed by applying the
proposed methods for the determination of two concen-
trations of OXM in pure form on three successive times,
and the results are listed in Table 3.
b. Intermediate precision
It was performed through repeated analysis of OXM in
pure form, using the concentrations showed in Table 3 for a
period of three successive days. The results are summarized
in Table 3.
Robustness of the method
The robustness ofthe method adoptedis demonstrated by the
constancy of the fluorescence intensity with the deliberated
Table 2 Application of the proposed and official methods to the
determination of Oxamniquine in pure form
Parameters Spectrofluorimetric
method
Official method
[2]
No. of experiments 6 3
Mean found (%) 100.13 100.09
± SD 0.68 0.87
% RSD 0.68 0.87
Variance 0.462 0.76
Student’s t value 0.081 (2.31)
Variance ratio F test 1.65 (5.41)
Figures between parentheses are the tabulated t and F values
respectively, at p=0.05 [27]
Table 3 Validation of the proposed method for the determination of
oxamniquine in pure form
Sample
concentration
% Recovery
(repeatability)
% Recovery intermediate
precision
0.08 μgm l
−1 99.64 101.08
100.72 99.28
101.44 100.89
X′ 100.60 100.42
± SD 0.91 0.99
%RSD 0.91 0.99
% Error 0.53 0.57
0.2 μgm l
−1 99.74 101.05
100.44 100.53
101.29 98.95
X′ 100.49 100.18
± SD 0.78 1.09
%RSD 0.78 1.09
% Error 0.45 0.63
Table 4 Application of the proposed methods to the determination of
oxamniquine in capsules
Preparations % Recovery
Proposed method Official method [2]
Vansil capsules (250 mg
oxamniquine/capsule)
98.25
101.00
99.38
99.80
99.30
Mean found (%)± SD 99.55 ± 0.99 100.56 ± 0.77
t value 1.67
F value 1.66
The tabulated values of t and F are (2.37) and (6.59) respectively, at
p=0.05 [27]
Table 5 Application of the proposed methods to the determination of
oxamniquine in spiked human plasma
Sample Amount added
(μgm l
−1)
Amount found
(μgm l
−1)
% Recovery
1-a-Plasma (inter-
day precision)
0.02 0.01957 97.85
0.04 0.03856 96.40
0.10 0.09754 97.54
0.20 0.19856 99.28
Mean 97.77
± SD 1.19
1-b-Plasma (inter-
day precision)
0.20 0.1914 95.70
0.20 0.1969 98.45
0.20 0.1948 97.40
0.20 0.1955 97.75
0.20 0.1979 98.95
0.20 0.1945 97.25
Mean 97.58
± SD 1.13
Each result is the average of three separate determinations
J Fluoresc (2008) 18:349–355 353 353minor changes in the experimental parameters such as
change in the volume of dansyl chloride (0.001%), 0.7 ±
0.1 ml, the change in reaction time 35 ± 5 min and the
change in dilution time 15 ± 5 min. These minor changes
that may take place during the experimental operation didn’t
affect the fluorescence intensity of the reaction product.
Pharmaceutical applications
The proposed methods were then applied to the determina-
tion of OXM in its capsules. The methods were tested for
linearity, specificity, accuracy, repeatability and precision
according to ICH Q2B recommendations.
Specificity
The specificity of the method was investigated by observ-
ing any interference encountered from the common capsule
excepients, such as talc, lactose, starch, avisil, gelatine, and
magnesium stearate. These excepients did not interfere with
the proposed method.
Accuracy
The results of the proposed methods were statistically
compared with those obtained using the official method
[2]. Statistical analysis [27] of the results, using Student’s
t test and variance ratio F test revealed no significant
difference between the performance of the proposed and
reference methods regarding the accuracy and precision,
respectively (Table 4).
Analysis of biological fluid
The high sensitivity of the proposed method allowed the
determinationofOXM in spiked human plasma.Oxamniquine
is readily absorbed following oral ingestion, and a peak
concentration in plasma occurs within about 3 h. The presence
of food significantly delays absorption and limits the concen-
tration achieved in plasma during the first several hours after
administration. Urinary excretion is the major route of
elimination in man [28]. Oxamniquine is given orally in a
dose of 250 mg three times daily; this leads to a final blood
level concentration of about 5 μgm l
−1 i.e. higher than the
upper limit of the working concentration range of the
proposed method. The high sensitivity of the proposed
method allowed the determination of OXM in spiked human
plasma. The results are shown in Table 5.
The extraction procedure described by Woolhouse and
Wood [7] was adopted here. The results are satisfactorily
accurate and precise.
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Scheme 1 Proposed reaction
pathway between dansyl
chloride and oxamniquine
354 J Fluoresc (2008) 18:349–355Precision The within-day precision was evaluated through
replicate analysis of Plasma samples spiked with different
concentrationsofthedrug.Thepercentagerecoveriesbasedon
the average of four separate determinations were 97.77 ± 1.19,
thus indicating the high precision of the method (Table 5).
Theinter-dayprecisionwasalsoevaluatedthroughreplicate
analysisofplasmasamplesspikedwith0.2μgm l
−1 of drug on
four successive days. The percentage recoveries based on the
average of four separate determinations were 97.58 ± 1.13.
The results are shown in Table 5.
Mechanism of the reaction
The stoichiometry of the reaction was studied adopting the
limiting logarithmic method [29]. The fluorescence intensity
of the reaction product was alternatively measured in the
presence of excess of either dansyl chloride or OXM. A plot
of log fluorescence versus log [dansyl chloride] and log
[OXM] gave straight lines, the values of the slopes are 0.901
and 0.984 respectively (Fig. 6). Hence, it is concluded that,
the molar reactivity of the reaction is 0.901/0.984, i.e. the
reaction proceeds in the ratio of 1:1. Based on the observed
molar reactivity of the reaction, and depending on the
presence of secondary amino group and by analogy to
similar reports dealing with the reaction of dansyl chloride
with compounds containing secondary amino group, the
reaction pathway proposed in Scheme 1 is presented.
Conclusion
The proposed method has the advantage of being simple,
sensitive and suitable for routine analysis in quality control
laboratory. Also, it is suitable for the determination of
oxamniquine in spiked human plasma with minimum
detection limit lower than the reported value. In addition,
it could be applied to the determination of OXM in its
pharmaceutical preparation.
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